Desmidt Thomas, Hommet Caroline, Camus Vincent
CHRU de Tours, Tours, France, Inserm U930, Tours, France.
CHRU de Tours, Tours, France, Université François-Rabelais, Tours, France, Inserm U930, Tours, France.
Geriatr Psychol Neuropsychiatr Vieil. 2016 Sep 1;14(3):300-6. doi: 10.1684/pnv.2016.0621.
Behavioral and psychological symptoms of dementia (BPSD) are frequent in Alzheimer's disease (AD). They are associated with disability and suffering for both the patients and their caregivers. Even if BPSD are now well diagnosed and characterized by standardized tools, their treatment remains often challenging in clinical setting because of the frequent and severe side effects of the psychotropic drugs when used in this indication. Evidence-based data confirm that antipsychotics and antidepressants are efficient for the treatment of BPSD but have a poor tolerance profile and their use is problematic. Use of cholinesterase inhibitors and memantine, whom French authorities have questioned the relevance in 2008, also have a significant efficacy on non-cognitive symptoms of AD. Therefore, and although their tolerance profile is considered unsatisfying, they keep an indication in patients with AD and BPSD.
痴呆的行为和心理症状(BPSD)在阿尔茨海默病(AD)中很常见。它们给患者及其照顾者带来残疾和痛苦。即使现在BPSD已通过标准化工具得到很好的诊断和特征描述,但由于精神药物用于该适应症时频繁且严重的副作用,其治疗在临床环境中仍然常常具有挑战性。循证数据证实,抗精神病药和抗抑郁药对BPSD的治疗有效,但耐受性较差,其使用存在问题。胆碱酯酶抑制剂和美金刚在2008年受到法国当局对其相关性的质疑,它们对AD的非认知症状也有显著疗效。因此,尽管它们的耐受性被认为不令人满意,但在患有AD和BPSD的患者中仍有适应症。